IBO
Impact Biomedical Inc.
$0.45
+0.00 (+0.00%)
At close · Jul 8
Market Cap
$48.70M
Shares
107,821,231
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.45
Open$0.45
Day$0.45–0.47
52W$0.37–0.83
Avg vol 30d74K
Short int621K · 0.6% float · 6.4d
Short vol36%
DataSep 2024–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
−19%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
18%
mid-range
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−6%
trailing
YTD return
−11%
this year
Relative strength
−14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-13% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.58% of float · ▼ -17.2% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
21 holders — mid 1-yr range
Squeeze score
49
elevated · 0–100
Fundamentals
Revenue growth
−36%
Y/Y
EPS growth
+83%
Y/Y
Balance sheet
$11.9M
net debt
Quant / Vol
risk profile
Volatility
120%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
−19%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
18%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-13% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.58% of float · ▼ -17.2% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
21 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 18%
52-wk high $1
vs 200-day avg -17%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IBO
this stock
Impact Biomedical Inc.
|
$48.70M | -10.5% | — | — | 0.6% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IBO | -1.7% | -19.3% | -6.4% | -1.7% | -10.5% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -2.7% | -20.7% | -14.0% | -1.9% | -20.2% |